Johnson & Johnson
JNJ
$230.65
+2.01%
Johnson & Johnson is the world's largest and most diverse healthcare firm, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company is a dominant market leader with a century-long legacy, distinguished by its massive scale, diversified revenue streams, and a fortress balance sheet that supports its status as a Dividend Aristocrat. The current investor narrative centers on the company's post-Kenvue divestiture transformation into a pure-play healthcare entity, with debates focusing on the growth trajectory of its Innovative Medicine pipeline to offset looming biosimilar competition for key drugs like Stelara, as highlighted in recent earnings reports, and its positioning amid evolving U.S. drug pricing and tariff policies.…
JNJ
Johnson & Johnson
$230.65
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: JNJ is a Hold for existing investors and a Buy on Pullbacks for new capital. The core thesis is that the stock offers a high-quality, defensive equity with a compelling long-term growth and income story, but its near-term upside is capped by Stelara headwinds and a premium valuation, making entry timing critical. This aligns with a mixed but leaning bullish analyst consensus.
Supporting Evidence: The Hold rating is supported by four key data points: 1) A premium but not excessive forward PE of 18.44x, 2) Solid underlying revenue growth of 9.08% YoY in Q4, 3) Exceptional financial strength evidenced by a 32.87% ROE and massive FCF generation, and 4) A substantial +37% implied upside to the average analyst target price of ~$321. However, the stock's recent 1-month underperformance (-1.31% vs. SPY +7.36%) and proximity to its 52-week high suggest limited near-term catalysts for multiple expansion.
Risks & Conditions: The two biggest risks to the thesis are an acceleration in Stelara's sales decline and a sector-wide de-rating that compresses its premium PE multiple. This Hold would upgrade to a Buy if the PE compressed toward 17x (offering a better margin of safety) or if Q2/Q3 2026 earnings demonstrate clear pipeline-driven growth offsetting Stelara weakness. It would downgrade to Sell if revenue growth decelerates below 5% YoY or if net margins contract significantly. The stock is currently fairly valued to slightly overvalued relative to pharma peers but offers relative value within its own historical context.
Sign up to view all
JNJ 12-Month Price Forecast
The 12-month outlook for JNJ is one of guarded optimism tempered by near-term execution risk. The base case (60% probability) of grinding higher towards $300 is most likely, driven by stable execution and its defensive characteristics. The substantial bull-case upside relies on flawless pipeline execution and multiple expansion, while the bear case, though low probability, is defined by a specific, known risk (Stelara). The stance is neutral due to the balanced risk/reward at current levels; it would turn bullish on a pullback to ~$220 or on clear evidence of pipeline offset in upcoming earnings, and bearish if Stelara weakness accelerates in H2 2026.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $299.85 and implied upside of +30.0% versus the current price.
Average Target
$299.85
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$185 - $300
Analyst target range
Analyst coverage is substantial, with 15 firms providing estimates, indicating strong institutional interest. The consensus recommendation leans bullish, as evidenced by recent actions from firms like Morgan Stanley upgrading to 'Overweight' and RBC Capital maintaining 'Outperform', though a mix of 'Buy', 'Hold', and 'Neutral' ratings exists. The average target price implied by the estimated EPS of $17.43 and the forward PE of 18.44x is approximately $321, which would represent a significant +37% upside from the current price of $234.18, signaling strong analyst conviction in the stock's fundamental value. The target range, derived from estimated EPS lows of $16.86 and highs of $17.85, suggests a relatively tight spread, indicating higher consensus and conviction among analysts; the high-end targets likely assume successful pipeline execution and multiple expansion, while the low-end targets may factor in competitive pressures and regulatory risks. The recent institutional rating actions show a pattern of reaffirmations and selective upgrades, reinforcing a stable-to-positive sentiment backdrop for the stock.
Bulls vs Bears: JNJ Investment Factors
The bull case, anchored by strong analyst conviction (+37% upside), a fortress financial profile, and defensive low-beta characteristics, currently holds stronger evidence. However, the bear case presents a credible and specific near-term challenge centered on Stelara's sales decline. The single most important tension in the investment debate is the race between JNJ's Innovative Medicine pipeline growth and the erosion from Stelara's biosimilar competition. The resolution of this tension over the next few quarters will be the primary determinant of whether the stock can realize its substantial analyst-projected upside or succumb to valuation compression.
Bullish
- Strong Analyst Conviction & Upside: Analysts project an average target price of approximately $321 based on an estimated EPS of $17.43 and a forward PE of 18.44x, implying a significant +37% upside from the current price of $234.18. The tight spread between low ($16.86) and high ($17.85) EPS estimates indicates high consensus and conviction in the company's near-term earnings power.
- Exceptional Financial Fortress: JNJ boasts a fortress balance sheet with a low debt-to-equity ratio of 0.59 and generates massive free cash flow of $19.70 billion TTM. This provides ample liquidity to fund its dividend (payout ratio 46.2%), share repurchases, and strategic M&A without financial strain, underpinning its Dividend Aristocrat status.
- Post-Divestiture Growth Momentum: As a pure-play healthcare entity, JNJ delivered robust Q4 2025 revenue growth of 9.08% YoY to $24.56 billion, driven by its Innovative Medicine segment ($15.76B). The company's trailing PE of 18.81x trades below its own 5-year historical average, suggesting relative value if this growth trajectory is sustained.
- Defensive Profile with Low Volatility: The stock's beta of 0.329 indicates it is approximately 67% less volatile than the broader market (SPY), a characteristic defensive trait. This low systematic risk, combined with a 48.71% 1-year price gain, offers an attractive risk-adjusted return profile for conservative portfolios.
Bearish
- Key Drug Stelara Faces Headwinds: Recent Q1 2026 earnings reports were overshadowed by a 'steep sales decline' for its key drug Stelara, creating a significant near-term headwind. This validates the central bear debate on whether the Innovative Medicine pipeline can fully offset this looming biosimilar competition.
- Premium Valuation vs. Pharma Peers: JNJ's trailing PE of 18.81x trades at a premium to the typical large-cap pharmaceutical peer, which often trades in the low-to-mid teens. This premium, justified by diversification and balance sheet strength, is vulnerable to compression if growth decelerates or sector multiples contract.
- Recent Underperformance & Technical Resistance: The stock is down -1.31% over the past month, significantly underperforming the SPY's +7.36% gain, indicating potential sector rotation or profit-taking. Trading at 83% of its 52-week range ($146.12 to $251.71), it faces immediate technical resistance near its 52-week high of $251.71.
- Regulatory & Pricing Policy Risks: Recent news highlights the threat of 100% tariffs on drugmakers without pricing deals from the Trump administration. While JNJ may be shielded, this creates a stark regulatory divide and underscores the persistent overhang of U.S. drug pricing policy uncertainty on the sector.
JNJ Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +48.71%. As of the latest close at $234.18, the price is trading at approximately 83% of its 52-week range ($146.12 to $251.71), positioning it closer to recent highs, which reflects strong investor confidence but also suggests limited near-term upside before encountering significant resistance. Recent momentum shows a divergence, with the stock down -1.31% over the past month, underperforming the SPY's +7.36% gain, while maintaining a solid +7.10% gain over the past three months; this 1-month underperformance indicates a potential consolidation or pullback within the broader uptrend, possibly driven by profit-taking or sector-specific headwinds. Key technical support is anchored at the 52-week low of $146.12, with immediate resistance at the 52-week high of $251.71; a decisive breakout above $251.71 would signal a resumption of the primary bull trend, while a breakdown below recent lows near $234 could test deeper support levels. The stock's beta of 0.329 indicates it is approximately 67% less volatile than the broader market (SPY), which is characteristic of a defensive healthcare giant and implies lower systematic risk for portfolio allocations.
Beta
0.33
0.33x market volatility
Max Drawdown
-11.8%
Largest decline past year
52-Week Range
$146-$252
Price range past year
Annual Return
+48.4%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | +8.5% |
| 3m | +4.8% | +2.8% |
| 6m | +21.1% | +4.6% |
| 1y | +48.4% | +32.3% |
| ytd | +11.2% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth is positive but shows some quarterly volatility; the most recent Q4 2025 revenue was $24.56 billion, representing a solid 9.08% year-over-year growth, though this follows a Q3 2025 revenue of $23.99 billion, indicating a sequential increase. The Innovative Medicine segment, at $15.76 billion for the latest period, is the primary growth driver, significantly outpacing the MedTech segment's $8.80 billion. The company is highly profitable, with Q4 2025 net income of $5.12 billion and a robust gross margin of 86.37%; however, comparing sequential quarters, the Q4 gross margin of 86.37% expanded significantly from Q3's 69.56%, though this was partly due to a one-time benefit, while the net margin was a healthy 20.83%. The balance sheet and cash flow are exceptionally strong, with a conservative debt-to-equity ratio of 0.59, a return on equity of 32.87%, and substantial free cash flow generation, with TTM free cash flow of $19.70 billion; this powerful cash engine, coupled with a current ratio of 1.03, provides ample liquidity to fund dividends, share repurchases, and strategic investments without reliance on excessive external financing.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the consistently positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 18.81x, while the forward PE is slightly lower at 18.44x; the narrow gap between trailing and forward multiples suggests the market anticipates only modest earnings growth in the near term. Compared to sector averages, JNJ's trailing PE of 18.81x trades at a premium to the typical large-cap pharmaceutical peer, which often trades in the low-to-mid teens, reflecting a valuation premium justified by its superior diversification, AAA-rated balance sheet, and reliable dividend. Historically, the current trailing PE of 18.81x sits below the stock's own 5-year historical average, which has often ranged into the low 20s, indicating the stock is not at peak valuation and may offer relative value within its own historical context, assuming fundamentals remain intact.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's primary financial risk is not solvency—its 0.59 debt-to-equity ratio and $19.7B TTM FCF are exemplary—but rather earnings volatility and growth sustainability. The company faces significant revenue concentration risk within its Innovative Medicine segment, which drove $15.76B of Q4 sales. A steep decline in Stelara sales, as recently reported, directly pressures this key growth engine. Furthermore, sequential gross margin volatility (from 69.56% in Q3 to 86.37% in Q4) indicates profitability can be impacted by one-time benefits and mix, creating potential for earnings misses if such tailwinds abate.
Market & Competitive Risks: The stock trades at a premium valuation with a trailing PE of 18.81x versus typical pharma peers in the low-to-mid teens, creating valuation compression risk if growth decelerates or if rising interest rates pressure equity multiples. Externally, the evolving U.S. drug pricing landscape, highlighted by recent news on potential 100% tariffs for non-compliant firms, poses a persistent regulatory overhang. While JNJ's low beta of 0.329 offers defensive appeal, it also implies the stock may underperform in strong bull markets, as evidenced by its -8.67% relative strength versus the SPY over the past month.
Worst-Case Scenario: The worst-case scenario involves a faster-than-anticipated decline in Stelara sales coinciding with pipeline setbacks (e.g., clinical trial failures for key pipeline assets) and a sector-wide de-rating of pharma multiples due to aggressive drug pricing policies. This could trigger a wave of analyst downgrades and a re-rating towards the lower end of its historical PE range. A realistic downside could see the stock retreat to its 52-week low of $146.12, representing a -38% decline from the current price of $234.18. A more probable adverse scenario, aligning with analyst low EPS estimates, might imply a downside to approximately $311 based on the low-end PE, but a break below key technical support could see a steeper fall.
FAQ
The key risks are, in order of severity: 1) Product Concentration: A steep sales decline for key drug Stelara, as recently reported, directly pressures the largest growth segment (Innovative Medicine). 2) Valuation Compression: A premium trailing PE of 18.81x could contract if growth decelerates or sector multiples fall. 3) Regulatory: Evolving U.S. drug pricing policies and tariff threats, as highlighted in recent news, create an uncertain backdrop. 4) Pipeline Execution: Failure of new drugs to adequately offset patent expiries could stall long-term growth. The company's low beta and strong cash flow mitigate but do not eliminate these risks.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $290-$310, driven by meeting consensus EPS of ~$17.43 and a stable PE multiple. The Bull Case (30% probability) targets $310-$330 on successful pipeline execution and multiple expansion. The Bear Case (10% probability) warns of a drop to $260-$280 if Stelara declines accelerate and multiples compress. The average analyst target implies a price of ~$321 (+37% upside). The base case is most likely, contingent on JNJ's pipeline growth offsetting known Stelara headwinds as guided.
JNJ is fairly valued to slightly overvalued on an absolute basis but may offer relative value historically. Its forward PE of 18.44x trades at a premium to the typical large-cap pharma peer (low-to-mid teens), justified by its superior diversification and AAA-rated balance sheet. However, this PE sits below the stock's own 5-year historical average, which has often been in the low 20s. The valuation implies the market expects mid-single-digit earnings growth and is paying for stability, not hyper-growth. A discount to its historical range suggests it is not at peak valuation.
JNJ is a good buy for long-term, income-oriented investors seeking defensive exposure and are willing to accept moderate near-term volatility. The stock offers a compelling +37% upside to analyst targets, a strong 2.46% dividend yield, and a fortress balance sheet. However, the steep decline in Stelara sales creates a near-term headwind, making the current price of $234.18 less attractive for immediate, full-position entry. It is best bought on market pullbacks or weakness below $225 to improve the margin of safety.
JNJ is unequivocally suitable for long-term investment with a minimum suggested holding period of 3-5 years. Its low beta (0.329) and dividend aristocrat status make it a poor candidate for short-term trading, as it typically exhibits lower volatility and may underperform in raging bull markets. The long-term thesis is based on the company's ability to reinvent its drug portfolio over time, supported by its massive R&D budget and financial strength. Investors should view it as a foundational, buy-and-hold component of a diversified portfolio, not a tactical trade.